Are adalimumab and certolizumab pegol effective in the treatment of Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print
Answer

Two other anti−TNF-α agents, adalimumab and certolizumab pegol, may be less immunogenic than infliximab and have shown efficacy in the treatment of Crohn disease that is refractory to the standard medical treatment of corticosteroids and inhibitors of DNA synthesis. [99]

Adalimumab is a recombinant human immunoglobulin (Ig) G1 monoclonal antibody that binds with a high affinity and specificity to human soluble TNF-α but not to lymphotoxin (TNF-β). Study results have shown that the immunogenicity of adalimumab is low compared with that of the chimeric agent infliximab. [99]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!